Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.

Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine. 2019 Nov 14;: Authors: Newall AT, Wood JG, Chen C, McIntyre P, Beutels P PMID: 31733945 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research

Related Links:

AbstractObjectivesPneumococcal and influenza vaccination rates have been suboptimal in studies of immunosuppressed patients. We aimed to assess barriers to and increase rates of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and influenza vaccination in this group. The primary endpoint was a statistically significant increase in adequate PPSV23 and influenza vaccination.MethodsIn 2017, rheumatology outpatients completed an anonymous questionnaire recording vaccination knowledge, status, and barriers. Simultaneously, a low-cost multifaceted quality improvement (QI) intervention was performed. All outpatients on oral...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
In November 2011, Malawi introduced the 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant schedule. Four to 7 years after introduction (2015 –2018), rolling prospective nasopharyngeal car...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Research article Source Type: research
[MSF] New Delhi/New York -Gavi, the Vaccine Alliance should immediately stop giving millions of dollars in financial incentives to pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) for the pneumococcal conjugate vaccine (PCV), said the international humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) ahead of the group's board meeting in New Delhi, India on December 4 and 5. Instead, Gavi should use the remaining US $262 million of the US $1.5 billion subsidy fund to support the ro
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Condition:   Pneumococcal Infections Intervention:   Biological: 13-valent pneumococcal conjugate vaccine Sponsors:   Telethon Kids Institute;   Papua New Guinea Institute of Medical Research Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: According to WHO-recommended thresholds for interpreting cost-effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective. PMID: 31774134 [PubMed - in process]
Source: Eastern Mediterranean Health Journal - Category: Middle East Health Tags: East Mediterr Health J Source Type: research
.
Source: Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
Conclusions: The S. pneumoniae isolates showed high genetic diversity in Shanghai and the prevalence of antimicrobial resistance was also high among S. pneumoniae isolates, most of which were multidrug-resistant. The spread of international resistance clones might contribute to the increase of resistant isolates. The PPV23 could protect against most pneumococcal capsular serotypes causing infection of adults in Shanghai.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
AbstractLimited protective effects of commercially available vaccines necessitate the development of novel pneumococcal vaccines. We recently reported a pneumococcal systemic vaccine containing two proteins, Pneumococcal surface protein A (PspA of family 1 and 2) and a bacterium-like particle-based pneumococcal mucosal vaccine containing PspA2 and PspA4 fragments, both eliciting broad protective immune responses. We had previously reported that subcutaneous (s.c.+s.c.+s.c.) immunization with the systemic vaccine induced more pronounced humoral serum IgG responses, while intranasal (i.n.+i.n.+i.n.) immunization with the muc...
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Australia Health | Meningitis Vaccine | Pneomococcal Vaccine | Vaccines